一、回购股份的基本情况 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ■ 三、其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第7号一一回购股 份》等相关规定，在回购期限内根据市场情况择机做出回购决策并予以实施，同时根据回购股份事项进 展情况及时履行信息披露义务，敬请广大投资者注意投资风险。 特此公告。 济民健康管理股份有限公司董事会 2025年8月1日 济民健康管理股份有限公司(以下简称"公司")于2025年3月28日召开第五届董事会第十七次会议，审议 通过了《关于以集中竞价交易方式回购股份方案的议案》，同意公司使用自有资金及金融机构借款以集 中竞价交易方式回购公司股份，回购价格不超过人民币10元/股（含）；回购资金总额不低于人民币 10,000万元（含）且不超过人民币20,000万元（含）；回购期限为自董事会审议通过回购方案之日起不 超过12个月。具体内容详见公司于2025年3月29日在上海证券交易所网站披露的《公司关于 ...

Group 1 - The stock price of Jimin Health is reported at 6.92 yuan, down 0.15 yuan from the previous trading day, representing a decline of 2.12% [1] - The trading volume for the day was 89,780 hands, with a transaction amount of 0.63 million yuan [1] - Jimin Health operates in the pharmaceutical manufacturing industry, with its main business segments including pharmaceutical manufacturing, medical services, and pharmaceutical trade [1] Group 2 - According to the 2024 annual report, the pharmaceutical manufacturing business accounts for 55.95% of total revenue, while medical services contribute 41.43% [1] - As of July 31, the company has repurchased 2.01 million shares, representing 0.38% of the total share capital, with a repurchase amount of 12.09 million yuan [1] - In the first quarter of 2025, the company reported revenue of 181 million yuan, with a net profit loss of 13.64 million yuan [1] Group 3 - Data shows that on July 31, Jimin Health experienced a net outflow of main funds amounting to 16.57 million yuan, which is 0.46% of the circulating market value [1]

证券日报网讯7月31日晚间，济民健康（603222）发布公告称，2025年7月份，公司未实施回购。截至 2025年7月31日，公司通过集中竞价交易方式累计回购股份2，005，500股，占公司总股本的比例为 0.3819%。 ...

Group 1 - The core point of the article is that Jimin Health has announced a share buyback program, repurchasing approximately 2.01 million shares, which accounts for 0.3819% of the total share capital, with a total expenditure of about 12.09 million yuan [2] Group 2 - As of July 31, 2025, the company has conducted the share buyback through centralized bidding, with the highest purchase price being 6.13 yuan per share and the lowest at 5.87 yuan per share [2] - For the fiscal year 2024, the revenue composition of Jimin Health is as follows: pharmaceutical manufacturing accounts for 55.95%, medical services for 41.43%, pharmaceutical trading for 1.75%, and other businesses for 0.87% [2]

| 回购方案首次披露日 | 2025/3/29 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 12 个月 | | 预计回购金额 | 10,000万元~20,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 □为维护公司价值及股东权益 | | 累计已回购股数 | 200.55万股 | | 累计已回购股数占总股本比例 | 0.38% | | 累计已回购金额 | 1,208.90万元 | | 实际回购价格区间 | 5.87元/股~6.13元/股 | 一、回购股份的基本情况 济民健康管理股份有限公司(以下简称"公司")于 2025 年 3 月 28 日召开第 五届董事会第十七次会议，审议通过了《关于以集中竞价交易方式回购股份方案 的议案》，同意公司使用自有资金及金融机构借款以集中竞价交易方式回购公司股 份，回购价格不超过人民币 10 元/股（含）；回购资金总额不低于人民币 10,000 万元（含）且不超过人民币 20,000 万元（含）；回购期限为自董事会审议通过回 购方案之日起不超过 12 个月。具体内容详见公司于 20 ...

格隆汇7月31日丨济民健康（维权）(603222.SH)公布，2025年7月，公司未实施回购。截止2025年7月31 日，公司通过集中竞价交易方式累计回购股份2,005,500股，占公司总股本的比例为0.3819%，购买的最 高价为6.13元/股，最低价为5.87元/股，已支付的总金额为12,088,967.50元（不含交易费用）。上述回购 符合相关法律法规的规定及公司既定的回购股份方案。 ...

Group 1 - The company expects a net profit attributable to the parent company for the first half of 2025 to be between -55 million yuan and -46 million yuan, indicating a significant loss compared to a profit of 25.45 million yuan in the same period last year [2][3] - The expected net profit excluding non-recurring gains and losses for the first half of 2025 is also projected to be between -55 million yuan and -46 million yuan [2][3] - The decline in performance is primarily attributed to a decrease in sales revenue of safety syringes and pre-filled catheter flushing devices due to the impact of the "He Qinghong seal engraving incident" and U.S. tariff policies, leading to a 40% drop in export revenue and an 82% decline in gross profit for safety syringes [2][3] Group 2 - The company has further made a provision for inventory impairment of approximately 20 million yuan for pre-filled catheter flushing devices and safety syringes based on cautious principles and current market sales conditions [3] - The sales revenue of pre-filled catheter flushing devices and safety syringes (domestic sales) has decreased by approximately 92% compared to the same period last year, significantly reducing the profits from these products [2][3] - The performance forecast is based on preliminary estimates and has not been audited by an accounting firm, with no significant uncertainties expected to affect the accuracy of the forecast [3]

[Current Period Performance Forecast](index=1&type=section&id=Item%20I.%20Current%20Period%20Performance%20Forecast) The company forecasts a net loss for H1 2025, with attributable net profit expected between -55 million and -46 million yuan, a stark reversal from the prior year's profit H1 2025 Performance Forecast vs. Prior Year | Indicator | H1 2025 (Forecast) | H1 2024 (Prior Year) | | :--- | :--- | :--- | | Net Profit Attributable to Parent Company (Million Yuan) | -55 to -46 | 25.4450 | | Net Profit Attributable to Parent Company (Excluding Non-Recurring Items) (Million Yuan) | -55 to -46 | 24.4007 | - This performance forecast is a preliminary estimate based on the company's operating conditions and has not been audited by a certified public accounting firm[4](index=4&type=chunk) [Prior Period Operating Performance](index=1&type=section&id=Item%20II.%20Prior%20Period%20Operating%20Performance) In H1 2024, the company reported a net profit of **25.4450 million yuan** attributable to the parent company, with earnings per share of **0.05 yuan** H1 2024 Performance Review | Indicator | Amount | | :--- | :--- | | Net Profit Attributable to Parent Company (Million Yuan) | 25.4450 | | Net Profit Attributable to Parent Company (Excluding Non-Recurring Items) (Million Yuan) | 24.4007 | | Earnings Per Share (Yuan) | 0.05 | [Main Reasons for Current Period Loss Forecast](index=2&type=section&id=Item%20III.%20Main%20Reasons%20for%20Current%20Period%20Loss%20Forecast) The H1 2025 loss is primarily due to declining export sales from US tariffs, a severe impact on domestic sales from the "He Qinghong Private Seal Incident," and significant inventory impairment provisions [Impact of US Tariffs: Decline in Export Business](index=2&type=section&id=3.1%20Impact%20of%20US%20Tariffs) US tariff policies severely impacted the export business of safety syringes, resulting in significant declines in both revenue and gross profit - Export revenue for safety syringes declined by approximately **40%**[7](index=7&type=chunk) - Export gross profit for safety syringes declined by approximately **82%**[7](index=7&type=chunk) [Impact of “He Qinghong Private Seal Incident”: Decline in Domestic Business](index=2&type=section&id=3.2%20Impact%20of%20%E2%80%9CHe%20Qinghong%20Private%20Seal%20Incident%E2%80%9D) The "He Qinghong Private Seal Incident" severely disrupted domestic sales channels, causing a sharp decline in revenue for pre-filled catheter flush syringes and safety syringes - Sales revenue for pre-filled catheter flush syringes and safety syringes (domestic sales) declined by approximately **92%** compared to the prior year due to this incident[8](index=8&type=chunk) [Provision for Inventory Impairment](index=2&type=section&id=3.3%20Provision%20for%20Inventory%20Impairment) Due to challenging market conditions and prudence, an additional **20 million yuan** inventory impairment provision was made for pre-filled catheter flush syringes and safety syringes, worsening the current loss - An additional inventory impairment provision of approximately **20 million yuan** was made for existing pre-filled catheter flush syringes and safety syringes[9](index=9&type=chunk) [Risk Warning and Other Notes](index=2&type=section&id=Item%20IV.%20Risk%20Warning%20and%20Other%20Notes) This performance forecast is preliminary and unaudited, with final financial data subject to the official H1 2025 report, urging investors to consider associated risks - This performance forecast is a preliminary estimate, unaudited by an accounting firm, and the company anticipates no significant uncertainties affecting its accuracy[10](index=10&type=chunk) - The specific and accurate financial data will be based on the company's officially disclosed H1 2025 report[11](index=11&type=chunk)

证券代码：603222 证券简称：济民健康 公告编号：2025-034 济民健康管理股份有限公司 关于回复《上海证券交易所关于公司 2024 年年 度报告的事后审核问询函》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 济民健康管理股份有限公司（以下简称："公司"）于近期收到上海证券交 易所下发的《关于济民健康管理股份有限公司 2024 年年度报告的事后审核问询 函》（上证公函【2025】0885 号）。公司收到年报问询函后高度重视，会同天 健会计师事务所（特殊普通合伙）就年报问询函提及的问题进行了逐项分析、核 实，现对相关问题回复如下： （一）涉案经销商名称、协议签订时间、涉及产品种类、金额/数量，截至 目前实际发生的退货比例及对应的资金补偿金额，相关《补充协议》法律效力及 与相关方沟通情况，并说明公安机关立案后的最新案件进展和公司已采取的应 对措施。 1、"何清红等人伪造公司印章"案涉案经销商情况 "何清红等人伪造公司印章"案涉及的产品主要为预充式导管冲洗器和安全 注射器，涉及的经销商分为两类，一级经销商和二级经销 ...

目 录 | 一、关于非标意见……………………………………………………第 | 1—9 | 页 | | --- | --- | --- | | 二、关于存货及销售情况 …………………………………………第 | 9—21 | 页 | | 三、关于商誉………………………………………………………第 | 21—32 | 页 | | 四、关于长期待摊费用……………………………………………第 | 32—37 | 页 | | 五、关于其他应收款………………………………………………第 | 37—43 | 页 | 问询函专项说明 天健函〔2025〕715 号 上海证券交易所： 由济民健康管理股份有限公司（以下简称济民健康或公司）转来的《关于济 民健康管理股份有限公司 2024 年年度报告的事后审核问询函》（上证公函【2025】 0885 号，以下简称问询函）奉悉。我们已对问询函中需要我们说明的财务事项 进行了审慎核查，现汇报说明如下。 本说明中除非另有说明，金额单位均为人民币万元；数值若出现合计数与各 分项加计之和尾数不符的情况，系由计算过程中四舍五入所致。 一、关于非标意见 年报及临时公告显示，公司原副总裁何清红及其团队涉嫌私刻公 ...